Buy Ibrushil 140mg - Ibrutinib Capsule Online, Ibrushil 140mg

Wishlist(0)

Ibrushil 140mg - Ibrutinib Capsule

Ibrushil 140mg contains Ibrutinib, a targeted oral chemotherapy used in the treatment of certain blood cancers such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia. It works by blocking a specific protein that helps cancer cells grow.

Select your size:

140mg

Choose Quantity:

+ Add To Cart

Buy Now

Add to wishlist

Description Product Details

General Information:

Generic Name: Ibrutinib

Brand Name: Ibrushil 140mg

Packing: Bottle of 30 or 120 capsules (depending on the market)

Strength: 140mg

Manufacturer: Shilpa Medicare Ltd.

Form: Oral Capsule

Category: Anticancer / Targeted Therapy / BTK Inhibitor

Product Intro:

Ibrushil 140mg is a Bruton’s tyrosine kinase (BTK) inhibitor that interrupts malignant B-cell proliferation. This capsule formulation offers a convenient oral treatment option for several hematological malignancies and provides improved progression-free survival rates in patients.

Uses:

Ibrushil is used to treat the following conditions:

Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)
Mantle Cell Lymphoma (MCL)
Waldenström's Macroglobulinemia (WM)
Marginal Zone Lymphoma (MZL)
Chronic Graft-Versus-Host Disease (cGVHD)

Storage Instructions:

Store at room temperature between 20°C to 25°C
Keep away from moisture and direct sunlight
Keep out of reach of children

How it Works (Mechanism of Action):

Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase (BTK), an enzyme crucial for B-cell receptor signaling. By blocking BTK, it inhibits malignant B-cell proliferation and survival, thereby slowing or stopping the growth of cancerous cells in blood and lymphoid tissues.

Side Effects:

Common Side Effects:

Diarrhea
Fatigue
Nausea
Bruising
Muscle or bone pain
Cough

Severe Side Effects:

Bleeding complications
Atrial fibrillation
Hypertension
Cytopenias (low blood counts)
Infections
Second primary malignancies

Dosage (Typical Recommended Dose):

MCL: 560 mg once daily (4 x 140mg capsules)
CLL/SLL/WM/cGVHD: 420 mg once daily (3 x 140mg capsules)
Always follow dosage as prescribed by a healthcare provider

Method of Administration:

Take orally with a glass of water
Swallow capsules whole; do not open, crush, or chew
Can be taken with or without food
Take at the same time each day for best results

Precautions:

Use with caution in patients with bleeding disorders or on anticoagulants
Monitor for infections, especially in immunocompromised patients
Regular ECG monitoring may be required due to risk of atrial fibrillation
Liver and kidney function should be assessed regularly
Avoid in pregnancy and lactation unless clearly necessary

Drug Interactions:

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) – may increase Ibrutinib levels
CYP3A4 inducers (e.g., rifampin, phenytoin) – may reduce effectiveness
Anticoagulants and antiplatelet agents – increased risk of bleeding
Avoid grapefruit juice and Seville oranges

Allergies:

Contraindicated in patients with known hypersensitivity to Ibrutinib or any excipients
Monitor for signs of rash, itching, or anaphylactic reaction

Overdose Information:

In case of overdose, monitor closely for signs of toxicity such as severe bleeding or arrhythmia
Provide supportive treatment
No specific antidote exists for Ibrutinib overdose

Missed Dose Instructions:

If a dose is missed, take it as soon as remembered on the same day
Do not take extra doses to make up for a missed dose
Skip the missed dose if it’s almost time for the next scheduled dose

Additional Notes:

Regular blood tests may be needed to monitor blood counts and organ function
Patients should be educated about bleeding risks and infection symptoms
Do not stop taking the medicine without consulting a healthcare provider